This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Small-Cap Winners & Losers

Small-cap stocks clung to the lower reaches of the broader market Thursday, largely moving in sync with the lukewarm Dow Jones Industrial Average.

Weighing things down were several health stocks, among them Progen Pharmaceuticals (PGLA), an Australia-based biotech that agreed to sell 6.9 million of its shares to institutional and other investors for a heavily discounted price of $4.75 apiece. Shares were plunging 19.9% to $4.83 in recent trading.

Monogram Biosciences (MGRM) lost a penny more than the Street had expected, according to Thomson Financial, and came in under sales estimates. Shares of the diagnostic-substances maker lost 11.4% to $1.64.

Fellow Californian Clarient (CLRT), purveyor of cancer-related diagnostic services, sank 13.2% to $2.10 after posting a first-quarter continuing-operations loss of 6 cents a share that missed two analysts' estimates by 2 cents.

Meanwhile, medical-products maker Thoratec (THOR - Get Report), of Pleasanton, Calif., plunged 14.5% to $17.01 despite edging out top- and bottom-line estimates for the first quarter. Town Sports International (CLUB - Get Report), a New York-based fitness-club operator, was off 9.4% to $20.54 after widening its GAAP-based first-quarter loss.

Small tech losers included semiconductor-equipment maker Axcelis Technologies (ACLS - Get Report), which reported first-quarter income that fell just under the Street's 4-cent-per-share targets, and Optelecom-NKF (OPTC), a communications-equipment maker that swung to a first-quarter loss vs. last year. Axcelis, based in Beverly, Mass., plummeted 19.2% to $6.63. Maryland-based Optelecom tumbled 19.8% to $6.71.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PGLA $0.14 3.57%
ACLS $3.20 -0.31%
CLUB $3.36 -1.47%
HNSN $0.90 -2.20%
THOR $45.39 -0.83%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs